This invention relates to a method of treating cancer in a human in need thereof comprising determining the presence or absence of a detectable amount of a gene product of the Neurofibromin 2 (NF2) gene in a sample from said human and administering to said human an effective amount of a focal adhesion kinase (FAK) inhibitor or a pharmaceutically acceptable salt thereof if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene or a functional fragment thereof in a sample from said human and administering to said human an effective amount of a focal adhesion kinase (FAK) inhibitor or a pharmaceutically acceptable salt thereof if no gene product or no isoform 1 gene product is detected.
